Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
China National Medicines's revenue for the
three
months ended in Jun. 2026 was ¥13,173 Mil.
Its revenue for the trailing twelve months (TTM) ended in Jun. 2026 was ¥53,563 Mil.
China National Medicines's Revenue per Share for the
three
months ended in Jun. 2026 was ¥17.46.
Its Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 was ¥70.99.
Good Sign:
China National Medicines Corp Ltd has shown predictable revenue and earnings growth.
During the past 12 months, the average Revenue per Share Growth Rate of China National Medicines was 4.10% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 4.90% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 4.80% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 7.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 13 years, China National Medicines's highest 3-Year average Revenue per Share Growth Rate was 37.20% per year. The lowest was -6.90% per year. And the median was 17.10% per year.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, China National Medicines's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China National Medicines Revenue vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, China National Medicines's Revenue distribution charts can be found below:
* The bar in red indicates where China National Medicines's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥53,563 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China National Medicines (SHSE:600511) has a Revenue of ¥53,563 Mil as of Jun. 2026. Revenue is the total amount a company generates as sales through its operations. View historical data on China National Medicines and its competitors.
Is China National Medicines' Revenue too high?
China National Medicines' current Revenue is ¥53,563 Mil. Overall, China National Medicines has a GF Score™ of 90/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does China National Medicines' Revenue compare to MCK and COR?
China National Medicines' Revenue of ¥53,563 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Medical Distribution company?
A good Revenue depends on the Medical Distribution industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on China National Medicines and its competitors. China National Medicines's current Revenue is ¥53,563 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China National Medicines stock overvalued right now?
Based on GuruFocus' analysis, China National Medicines (SHSE:600511) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥32.09, compared to a current price of ¥26.77 — trading 16.6% below its estimated fair value. The current Revenue is ¥53,563 Mil. China National Medicines' overall GF Score™ is 90/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For China National Medicines (SHSE:600511), the current Revenue is ¥53,563 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is China National Medicines (SHSE:600511) Overvalued in 2026?
Based on GuruFocus' analysis, China National Medicines stock appears to be undervalued.
The current stock price of ¥26.77 is trading 16.6% below its estimated GF Value™ of ¥32.09.
GuruFocus considers China National Medicines to be Modestly Undervalued.
Key valuation signals for SHSE:600511:
Revenue: ¥53,563 Mil
GF Value™: ¥32.09 vs. price of ¥26.77 (16.6% below fair value)
No single metric tells the full story. See the SHSE:600511 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
China National Medicines Corp Ltd focuses on producing special drugs and high-end prescription drugs. Its main goal is to provide customers with professional medical services. The company conducts its operations through two primary segments. The Commercial segment is mainly engaged in the sale of pharmaceuticals. The Others segment focuses on pharmaceutical manufacturing and logistics operations.
90GF Score
Get the complete analysis for SHSE:600511
Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600511 has been successfully added to your 
